- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AbbVie Inc (ABBV)
"AbbVie Inc stock price live, this page displays NYSE ABBV stock exchange data. View the ABBV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AbbVie Inc real time stock price chart below.
What Is the AbbVie Inc Stock Price Today?
The AbbVie Inc stock price today is 184.02.
What Is the Stock Symbol for AbbVie Inc?
The stock symbol for AbbVie Inc is ""ABBV.""
What Stock Exchange Does AbbVie Inc Trade On?
AbbVie Inc is listed and trades on the NYSE stock exchange.
Is AbbVie Inc a Good Stock to Buy?
Determining whether AbbVie Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABBV quote. (ISIN: US00287Y1091)"
What Is the AbbVie Inc Stock Price Today?
The AbbVie Inc stock price today is 184.02.
What Is the Stock Symbol for AbbVie Inc?
The stock symbol for AbbVie Inc is ""ABBV.""
What Stock Exchange Does AbbVie Inc Trade On?
AbbVie Inc is listed and trades on the NYSE stock exchange.
Is AbbVie Inc a Good Stock to Buy?
Determining whether AbbVie Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABBV quote. (ISIN: US00287Y1091)"
184.02
+2.34(+1.29%)
Closed·
After Hours
183.40-0.62(-0.34%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
180.52
184.07
52 wk Range
153.58
218.66
ABBV Scorecard
Full Analysis
Has raised its dividend for 12 consecutive years
ABBV is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
180.52184.07
52 wk Range
153.58218.66
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.56%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.56%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABBV Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
210.57
Upside
+14.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- FDA approves new lung cancer drug EMRELIS by AbbVie
- Investing.com
- FDA approves new lung cancer drug EMRELIS by AbbVie
- Investing.com
- AbbVie teams up with ADARx for siRNA therapies
- Investing.com
AbbVie Inc Company Profile
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc SWOT Analysis
Resilient Performance | AbbVie demonstrates strong financial results and strategic foresight in navigating Humira's patent cliff, with immunology drugs Skyrizi and Rinvoq exceeding expectations |
Portfolio Evolution | Explore AbbVie's transition from Humira dependency, focusing on the growth of its immunology portfolio and strategic acquisitions in oncology and neuroscience |
Market Positioning | Delve into AbbVie's competitive stance in the immunology market, its challenges in aesthetics, and the potential impact of biosimilar competition on market dynamics |
Future Prospects | Analysts maintain positive outlook with price targets ranging from $200 to $227, citing AbbVie's robust pipeline and growth potential in key therapeutic areas |
AbbVie Inc Earnings Call Summary for Q1/2025
- AbbVie beats Q1 expectations with adjusted EPS of $2.46 and revenue of $13.3B, exceeding forecasts by $550M
- Full-year EPS guidance raised to $12.09-$12.29, with high single-digit revenue growth projected through 2029
- Strong growth in SKYRIZI and RINVOQ sales offset HUMIRA declines; $10B investment planned for U.S. manufacturing
- Stock up 0.19% post-announcement; analysts see potential upside with targets ranging from $173 to $250 per share
- CEO highlights clear growth runway for next 8 years, expecting to exceed previous peak revenue post-HUMIRA LOE
Last Updated: 04/25/2025, 10:28 PM
Read Full TranscriptCompare ABBV to Peers and Sector
Metrics to compare | ABBV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABBVPeersSector | |
|---|---|---|---|---|
P/E Ratio | 77.2x | −2.7x | −0.5x | |
PEG Ratio | −2.54 | 0.03 | 0.00 | |
Price/Book | 226.0x | 3.3x | 2.6x | |
Price / LTM Sales | 5.6x | 10.2x | 2.9x | |
Upside (Analyst Target) | 12.8% | 47.1% | 45.8% | |
Fair Value Upside | Unlock | 17.5% | 8.6% | Unlock |
Analyst Ratings
16 Buy
12 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 210.57
(+14.43% Upside)
Earnings
Latest Release
Apr 25, 2025
EPS / Forecast
2.46 / 2.39
Revenue / Forecast
13.34B / 12.93B
People Also Watch
FAQ
What Is the AbbVie (ABBV) Stock Price Today?
The AbbVie stock price today is 184.02
What Stock Exchange Does AbbVie Trade On?
AbbVie is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for AbbVie?
The stock symbol for AbbVie is "ABBV."
Does AbbVie Pay Dividends? What’s The Current Dividend Yield?
The AbbVie dividend yield is 3.56%.
What Is the AbbVie Market Cap?
As of today, AbbVie market cap is 324.15B.
What Is AbbVie's Earnings Per Share (TTM)?
The AbbVie EPS (TTM) is 2.35.
When Is the Next AbbVie Earnings Date?
AbbVie will release its next earnings report on Jul 24, 2025.
From a Technical Analysis Perspective, Is ABBV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.